Hyperhomocysteinaemia is associated with osteoporosis in patients with Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 7, 2007, Pages 797-804

  Roblin, X ^a   Phelip, J M ^a   Genevois, M ^a   Ducros, V ^a   Bonaz, B ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; IMMUNOSUPPRESSIVE AGENT; MESALAZINE; SALAZOSULFAPYRIDINE;

ADULT; AGE; ARTICLE; BONE DENSITOMETRY; BONE MINERALIZATION; CROHN DISEASE; DISEASE DURATION; FEMALE; FOLIC ACID BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; SEX; SMOKING; VITAMIN BLOOD LEVEL;

ADULT; BONE DENSITY; CROHN DISEASE; DENSITOMETRY, X-RAY; FEMALE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; OSTEOPOROSIS; RISK FACTORS; VITAMIN B DEFICIENCY;

EID: 33947202303     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03260.x     Document Type: Article

References (38)

1. Papa A, De Stefano V, Danese S, et al. Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease. Am J Gastroenterol 2001; 96: 2677-82.
2. Maire F, Beaugerie L, Cohen M, et al. Factors associated with hyperhomocysteinemia in Crohn's disease. Gastroenterol Clin Biol 2001; 25: 745-8.
3. Romagnuolo J, Fedorak RN, Dias VC, Bamforth F, Teltscher M. Hyperhomocysteinemia and inflammatory bowel disease: prevalence and predictors in a cross-sectional study. Am J Gastroenterol 2001; 96: 2143-9.
4. Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 1995; 10: 250-6.
5. Roux C, Abitbol V, Chaussade S, et al. Bone loss in patients with inflammatory bowel disease: a prospective study. Osteoporos Int 1995; 5: 156-60.
6. Schoon EJ, van Nunen AB, Wouters RS, Stockbrugger RW, Russel MG. Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-based cohort. Scand J Gastroenterol Suppl 2000; 232: 43-7.
7. Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol 1998; 93: 1483-90.
8. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000; 133: 795-9.
9. Kaur M, Kabra M, Das GP, Suri M, Verma IC. Clinical and biochemical studies in homocystinuria. Indian Pediatr 1995; 32: 1067-75.
10. Golbahar J, Hamidi A, Aminzadeh MA, Omrani GR. Association of plasma folate, plasma total homocysteine, but not methylenetetrahydrofolate reductase C667T polymorphism, with bone mineral density in postmenopausal Iranian women: a cross-sectional study. Bone 2004; 35: 760-5.
11. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 2004; 350: 2033-41.
12. McLean RR, Jacques PF, Selhub J, et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 2004; 350: 2042-9.
13. Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995; 37: 71-6.
14. Roblin X, Paris F, Pellissier L, Le Gall S, Boudemaghe T. Influence of lipid-lowering drugs on homocysteine levels. Rev Med Interne 2002; 23: 735-6.
15. Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index. Gastroenterology 1976; 70: 439-444.
16. Tucker KL, Hannan MT, Qiao N, et al. Low plasma vitamin B12 is associated with lower BMD: the Framingham Osteoporosis Study. J Bone Miner Res 2005; 20: 152-8. Epub 2004 Oct 25.
17. Abrahamsen B, Madsen JS, Tofteng CL, et al. A common methylenetetrahydrofolate reductase (C677T) polymorphism is associated with low bone mineral density and increased fracture incidence after menopause: longitudinal data from the Danish osteoporosis prevention study. J Bone Miner Res 2003; 18: 723-9.
18. McLean RR, Karasik D, Selhub J, et al. Association of a common polymorphism in the methylenetetrahydrofolate reductase (MTHFR) gene with bone phenotypes depends on plasma folate status. J Bone Miner Res 2004; 19: 410-8. Epub 2003 Dec 22.
19. Quere I, Gris JC. Dauzat M Homocysteine and venous thrombosis. Semin Vasc Med 2005; 5: 183-9.
20. Roblin X, Germain E, Phelip JM, et al. Factors associated with hyperhomocysteinemia in inflammatory bowel disease: prospective study in 81 patients. Rev Med Interne 2005; 27: 106-10.
21. Khan M, Yamauchi M, Srisawasdi S, et al. Homocysteine decreases chondrocyte-mediated matrix mineralization in differentiating chick limb-bud mesenchymal cell micro-mass cultures. Bone 2001; 28: 387-98.
22. McKusick VA. Heritable Disorders of Connective Tissue. St Louis: C.V.Mosby, 1966: 155.
23. Jackson SH. The reaction of homocysteine with aldehyde: an explanation of the collagen defects in homocystinuria. Clin Chim Acta 1973; 3: 215-7.
24. Kim DJ, Koh JM, Lee O, et al. Homocysteine enhances apoptosis in human bone marrow stromal cells. Bone 2006; 39: 582-90.
25. Koh JM, Lee YS, Kim YS, et al. Homocysteine enhances bone resorption by stimulation of osteoclast formation and activity through increased intracellular ROS generation. J Bone Miner Res 2006; 21: 1003-11.
26. Schulte C, Dignass AU, Mann K, Goebell H. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis 1998; 4: 268-75.
27. Robinson RJ, al-Azzawi F, Iqbal SJ, et al. Osteoporosis and determinants of bone density in patients with Crohn's disease. Dig Dis Sci 1998; 43: 2500-6.
28. Ardizzone S, Bollani S, Bettica P, Bevilacqua M, Molteni P, Bianchi Porro G. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis. J Intern Med 2000; 247: 63-70.
29. Andreassen H, Hylander E, Rix M. Gender, age, and body weight are the major predictive factors for bone mineral density in Crohn's disease: a case-control cross-sectional study of 113 patients. Am J Gastroenterol 1999; 94: 824-8.
30. Laan RF, van Riel PL, van de Putte LB, van Erning LJ, van't Hof MA, Lemmens JA. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 1993; 15: 119.
31. Bernstein CN, Seeger LL, Anton PA, et al. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther 1996; 10: 777-86.
32. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut 1997; 40: 228-33.
33. Abreu MT, Geller JL, Vasiliauskas EA, et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J Clin Gastroenterol 2006; 40: 55-63.
34. Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995; 37: 71-6.
35. Robinson RJ, al-Azzawi F, Iqbal SJ, et al. Osteoporosis and determinants of bone density in patients with Crohn's disease. Dig Dis Sci. 1998; 43: 2500-6.
36. Vogelsang H, Schofl R, Tillinger W, Ferenci P, Gangl A. 25-hydroxyvitamin D absorption in patients with Crohn's disease and with pancreatic insufficiency. Wien Klin Wochenschr 1997; 109: 678-82.
37. Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K. Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial. JAMA 2005; 9: 1082-8.
38. Buchman AL. Population-based screening for celiac disease: improvement in morbidity and mortality from osteoporosis? Arch Intern Med 2005; 4: 370-2.